- Home
- TC vs PMN Comparison
TC vs PMN Comparison
Compare TC & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TC | PMN |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.0M | 34.6M |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | TC | PMN |
|---|---|---|
| Price | $10.30 | $17.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | 2.7K | ★ 50.9K |
| Earning Date | 03-26-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 110.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.29 |
| 52 Week High | $19.99 | $27.40 |
Technical Indicators
Market Signals| Indicator | TC | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 34.29 | 47.03 |
| Support Level | $8.93 | $0.42 |
| Resistance Level | $11.00 | $19.85 |
| Average True Range (ATR) | 0.56 | 3.00 |
| MACD | -0.12 | -0.94 |
| Stochastic Oscillator | 6.95 | 15.58 |
Price Performance
Historical ComparisonAbout TC TuanChe Limited
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.